Discovery of direct-acting small-molecule RIG-I agonists through creation of a selective CARD activation platform
In the authors' words
Abstract Retinoic acid-inducible gene-I (RIG-I) plays a pivotal role in recognizing and combating RNA viruses in humans, and it has become a drug target of significant interest. RIG-I agonists composed of dsRNA represent antiviral and antitumor therapies, however the development of small-molecule RIG-I agonists, with their potential for improved pharmacokinetics, remains an unmet need. Here, we report small-molecule RIG-I agonists that directly activate the RIG-I receptor protein. These agonists stimulate the first step in RIG-I signaling by triggering release of the signaling domains (CARDs) from an autorepressed form of the protein. This was achieved by developing a sensitive high-throughput screening (HTS) assay that directly monitors CARD expulsion through optical methods. The resulting screen hits were refined and optimized, leading to a specific RIG-I agonist that induces a robust interferon response. This study establishes a pharmacophore and assay for development of small molecules that precisely modulate RIG-I signaling.
In plain words AI summary
RIG-I is a human protein that detects and fights RNA viruses. The authors created a test to find small molecules that activate RIG-I directly. These molecules trigger release of the signaling parts (CARDs) from the inactive protein. They refined the best hits into a specific agonist that causes a strong interferon response. This work provides a starting point for developing small molecules that control RIG-I signaling.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Wednesday, October 21. Nature Communications. Peer-reviewed journal.